- Home
- EWTX
as 09-05-2025 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.5B | IPO Year: | 2021 |
| Target Price: | $39.89 | AVG Volume (30 days): | 782.1K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.60 - $38.12 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Russell Alan J | EWTX | Chief Scientific Officer | Aug 26 '25 | Sell | $14.60 | 100,000 | $1,459,760.00 | 23,400 | |
| Carruthers R Michael | EWTX | Chief Financial Officer | Aug 12 '25 | Sell | $13.39 | 1,428 | $19,124.35 | 86,162 | |
| MOORE JOHN R | EWTX | General Counsel | Aug 12 '25 | Sell | $13.39 | 2,098 | $28,097.26 | 10,214 | |
| Donovan Joanne M. | EWTX | CMO | Aug 12 '25 | Sell | $13.39 | 2,862 | $38,329.05 | 25,361 | |
| KOCH KEVIN | EWTX | President and CEO | Aug 12 '25 | Sell | $13.39 | 7,972 | $106,764.21 | 30,615 | |
| Derakhshan Behrad | EWTX | Chief Business Officer | Aug 12 '25 | Sell | $13.39 | 2,491 | $33,360.47 | 23,645 | |
| Russell Alan J | EWTX | Chief Scientific Officer | Aug 12 '25 | Sell | $13.39 | 1,907 | $25,539.31 | 23,400 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
TipRanks
2 months ago
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
MT Newswires
2 months ago
Wedbush Cuts Price Target on Edgewise Therapeutics to $35 From $40, Keeps Outperform Rating
MT Newswires
2 months ago
Edgewise Therapeutics Reports 'Positive' 3-Year Becker Data, Phase 2 Duchenne Muscular Dystrophy Findings for Sevasemten
PR Newswire
2 months ago
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
PR Newswire
3 months ago
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
Zacks
4 months ago
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Zacks
4 months ago
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
PR Newswire
4 months ago
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.